Condition
Her2-negative Tumor
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Unknown1
Clinical Trials (1)
Showing 1 of 1 trials
NCT03750396Phase 2Unknown
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Showing all 1 trials